Patents Examined by San Ming R. Hui
  • Patent number: 10463665
    Abstract: The present invention relates to a pharmaceutically acceptable acid addition salt of: (i) 9,10-dimethoxy-2-(2,4,6-trimethylphenylimino)-3-(N-carbamoyl-2-aminoethyl)-3,4,6,7-tetrahydro-2H-pyrimido[6,1-a]isoquinolin-4-one (RPL554); and (ii) ethane-1,2-disulfonic acid, ethanesulfonic acid, methanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, hydrochloric acid, hydrobromic acid, phosphoric acid or sulfuric acid.
    Type: Grant
    Filed: February 10, 2016
    Date of Patent: November 5, 2019
    Assignee: VERONA PHARMA PLC
    Inventors: Peter Lionel Spargo, Edward James French, Julian Scott Northen, John Mykytiuk
  • Patent number: 10463678
    Abstract: A method for contraception includes administering to a female daily, in a fourphasic dosing regimen during a time period of 24 successive days, an oral combination drug formulation of norethindrone acetate and ethinyl estradiol (EE), wherein doses in the second, third and fourth phases of the regimen increase by a predefined dose increment as compared to the corresponding doses administered during the previous phase, wherein the norethindrone acetate dose in the first phase is 1000 mcg, in the second phase is 1125 mcg, in the third phase is 1250 mcg, and in the fourth phase is 1375 mcg, wherein the EE dose in the first phase is 20 mcg, in the second phase is 22.5 mcg, in the third phase is 25 mcg, and in the fourth phase is 27.5 mcg, and wherein the fourphasic dosing regimen is followed by 4 days without norethindrone acetate and EE administration.
    Type: Grant
    Filed: September 24, 2018
    Date of Patent: November 5, 2019
    Assignee: ARSTAT, INC.
    Inventor: Arkady Rubin
  • Patent number: 10456398
    Abstract: The present invention relates to the treatment of acquired and genetic heart conditions in a subject by the inhibition of SGK1, including Long QT syndrome and cardiovascular disease, including dilated cardiomyopathy. Cardiovascular diseases treatable by SGK1 inhibition include heart failure, arrhythmia, ischemic injury, ischemic infarction, cardiac fibrosis, vascular proliferation, restenosis, dilated cardiomyopathy, and stent failure. The present invention also identifies selective inhibitors of SGK1. The method comprises administering to the subject a therapeutically effective amount of an inhibitor of SG.
    Type: Grant
    Filed: February 8, 2018
    Date of Patent: October 29, 2019
    Assignee: Beth Israel Deaconess Medical Center, Inc.
    Inventors: Anthony Rosenzweig, Saumya Das, Alan C. Rigby
  • Patent number: 10449189
    Abstract: Provided are a therapeutic agent and a pharmaceutical composition exerting an excellent prophylactic or therapeutic effect on fibrosis and symptoms associated with fibrosis. The therapeutic agent for fibrosis comprises 4-[2-fluoro-4-[[[(2-phenylacetyl)amino]thioxomethyl]amino]-phenoxy]-7-methoxy-N-methyl-6-quinolinecarboxamide or a salt thereof as an active ingredient.
    Type: Grant
    Filed: June 24, 2016
    Date of Patent: October 22, 2019
    Assignee: TAIHO PHARMACEUTICAL CO., LTD.
    Inventor: Akio Fujioka
  • Patent number: 10449194
    Abstract: The disclosure provides an extended release formulation of 5-fluorocytosine. In another aspect, a method of treating a fungal disease is provided. The method comprises administering to a subject in need thereof a fungus-treating effective amount of a composition comprising 5-fluorocytosine. In yet another aspect, a method of treating a cancer is provided. The method comprises administering to a subject in need thereof a sufficient amount of an expression vector to induce expression of cytosine deaminase which is capable of converting 5-fluorocytosine to 5-fluorouracil in cells of the cancer and a cancer-treating effective amount of a composition comprising 5-fluorocytosine.
    Type: Grant
    Filed: February 7, 2018
    Date of Patent: October 22, 2019
    Assignee: Tocagen Inc.
    Inventors: Harry E. Gruber, Douglas J. Jolly, Kay Olmstead
  • Patent number: 10434074
    Abstract: Methods and compositions for activating an EphA receptor can be used for identifying therapeutic agents for cancer.
    Type: Grant
    Filed: August 15, 2016
    Date of Patent: October 8, 2019
    Assignee: CASE WESTERN RESERVE UNIVERSITY
    Inventors: Bingcheng Wang, Eugene Myshkin, Hui Miao
  • Patent number: 10426751
    Abstract: A method of restoring activity in phenylalanine hydroxylase is provided. The method comprises exposing the phenylalanine hydroxylase to shikimic acid, a functionally equivalent analog thereof, a pharmaceutically acceptable salt of shikimic acid or analog thereof, or combinations thereof.
    Type: Grant
    Filed: January 8, 2016
    Date of Patent: October 1, 2019
    Assignee: McMaster University
    Inventor: Philip Britz-McKibbin
  • Patent number: 10426746
    Abstract: Methods of treating developmental disorders such as Angelman syndrome, Fragile X syndrome, Fragile X-associated tremor/ataxia syndrome (FXTAS), Autistic Spectrum Disorder, Autism, Asperger's syndrome, pervasive developmental disorder, Childhood Disintegrative Disorder, Rett syndrome, Landau-Kleffner Syndrome, Prader-Willi Syndrome, Tardive Dyskinesia, a seizure disorder and/or Williams Syndrome with a biguanide such as metformin, buformin, phenformin or a pharmaceutically acceptable salt thereof are provided. The methods provide therapeutic compositions that may be used to improve one or more symptoms of the developmental disorder.
    Type: Grant
    Filed: October 11, 2018
    Date of Patent: October 1, 2019
    Assignee: OVID THERAPEUTICS INC.
    Inventor: Matthew During
  • Patent number: 10413523
    Abstract: A composition which includes Phenylalanine, Serine, Glutamine and GABA (?-aminobutyric acid). The composition contains the essential amino acids Phenylalanine; Glutamine; the non-essential amino acid Serine; and GABA (?-aminobutyric acid) in concentrations effective to influence or modulate the neurotransmitter pentapeptide enkephalin. The composition may further comprise tetrahydrocannabinol (THC).
    Type: Grant
    Filed: November 16, 2017
    Date of Patent: September 17, 2019
    Assignee: BIOADATP, LLC
    Inventor: Kevin Meehan
  • Patent number: 10413561
    Abstract: Oral dosage forms of osteoclast inhibitors, such as neridronic acid, in an acid or a salt form, can be used to treat or alleviate pain or related conditions, such as complex regional pain syndrome.
    Type: Grant
    Filed: March 27, 2019
    Date of Patent: September 17, 2019
    Assignee: ANTECIP BIOVENTURES II LLC
    Inventor: Herriot Tabuteau
  • Patent number: 10406130
    Abstract: In various embodiments, the present invention provides methods of treating and/or preventing cardiovascular-related disease and, in particular, a method of reducing or preventing sdLDL oxidation in a subject, the method comprising administering to the subject a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof.
    Type: Grant
    Filed: January 25, 2017
    Date of Patent: September 10, 2019
    Assignee: Amarin Pharmaceuticals Ireland Limited
    Inventor: Richard Preston Mason
  • Patent number: 10398713
    Abstract: In one embodiment, the present application discloses methods of treating diseases and disorders with sulfasalazine and pharmaceutical formulations of sulfasalazine where the bioavailability of the sulfasalazine is increased. In another embodiment, the present application also provides dosing regimens for treating neurodegenerative diseases and disorders with compositions comprising sulfasalazine.
    Type: Grant
    Filed: April 17, 2018
    Date of Patent: September 3, 2019
    Assignee: Glialogix, Inc.
    Inventors: Thaddeus Cromwell Reeder, Mark Wade Moore, Douglas Alan Lorenz, David Keith Lyon
  • Patent number: 10398669
    Abstract: The present invention is directed to a liquid formulation comprising levothyroxine or a pharmaceutically acceptable salt thereof. The formulation of the present invention includes tromethamine, sodium iodide, and water and has a pH of about 9.0 to about 11.5. The liquid formulation according to the invention is stable and ready-to-use.
    Type: Grant
    Filed: September 11, 2017
    Date of Patent: September 3, 2019
    Assignee: Fresenius Kabi USA, LLC
    Inventors: Arunya Usayapant, Basma M. Ibrahim
  • Patent number: 10383834
    Abstract: Described herein are compositions and methods for intravenous administration of acetaminophen at a single dose level of less than about 1000 mg for the treatment or prevention of pain (e.g., postoperative pain) and/or fever.
    Type: Grant
    Filed: May 14, 2018
    Date of Patent: August 20, 2019
    Assignee: Mallinckrodt Hospital Products IP Limited
    Inventors: Mike Allan Royal, James Bradley Breitmeyer
  • Patent number: 10378068
    Abstract: Provided herein are methods of treating a subject having a cancer, methods of selecting a treatment for a subject having a cancer, methods of selecting a subject having a cancer for a treatment that does not include a Trk inhibitor, methods of determining the likelihood that a subject having a cancer will have a positive response to a treatment with a Trk inhibitor, methods of predicting the efficacy of a Trk inhibitor in a subject having cancer, methods of determining a subject's risk for developing a Trk inhibitor-resistant cancer, and methods of determining the presence of a Trk inhibitor-resistant cancer in a subject, based on the detection of a cell from a sample from the subject that has at least one of the point mutations in NTRK1 and/or NTRK2 and/or NTRK3.
    Type: Grant
    Filed: October 16, 2017
    Date of Patent: August 13, 2019
    Assignees: Loxo Oncology, Inc., Array BioPharma, Inc.
    Inventors: Nisha Nanda, Joshua H. Bilenker, James F. Blake, Gabrielle R. Kolakowski, Barbara J. Brandhuber, Steven W. Andrews
  • Patent number: 10369152
    Abstract: Provided herein are methods and compositions for the treatment and/or prevention of abnormal bone formation in a soft tissue. In certain embodiments, the methods and compositions treat and/or prevent a disease or disorder comprising abnormal bone formation in soft tissue. Exemplary diseases or disorders that can be treated with the methods and compositions described herein include, but are not limited to, heterotopic ossification diseases such as fibrodysplasia ossificans progressive, anklyosing spondylosis, traumatic heterotopic ossification, burn- or blast-injury associated heterotopic ossification, and joint replacement surgery associated heterotopic ossification.
    Type: Grant
    Filed: February 12, 2016
    Date of Patent: August 6, 2019
    Assignee: THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
    Inventors: Paul B. Yu, Jana Bagarova, Devaveena Dey
  • Patent number: 10370727
    Abstract: Provided herein are methods of treating a subject having a cancer, methods of selecting a treatment for a subject having a cancer, methods of selecting a subject having a cancer for a treatment that does not include a Trk inhibitor, methods of determining the likelihood that a subject having a cancer will have a positive response to a treatment with a Trk inhibitor, methods of predicting the efficacy of a Trk inhibitor in a subject having cancer, methods of determining a subject's risk for developing a Trk inhibitor-resistant cancer, and methods of determining the presence of a Trk inhibitor-resistant cancer in a subject, based on the detection of a cell from a sample from the subject that has at least one of the the point mutations in NTRK1 and/or NTRK2 and/or NTRK3.
    Type: Grant
    Filed: October 16, 2017
    Date of Patent: August 6, 2019
    Assignees: Loxo Oncology, Inc., Array BioPharma, Inc.
    Inventors: Nisha Nanda, Joshua H. Bilenker, James F. Blake, Gabrielle R. Kolakowski, Barbara J. Brandhuber, Steven W. Andrews
  • Patent number: 10365267
    Abstract: Described herein are methods and assays relating to the inhibition of sepiapterin reductase and measuring said inhibition by measuring the level of sepiapterin. In some embodiments, the methods can further relate to treating a subject with BH4 and/or BH2.
    Type: Grant
    Filed: October 29, 2015
    Date of Patent: July 30, 2019
    Assignee: CHILDREN'S MEDICAL CENTER CORPORATION
    Inventors: Clifford J. Woolf, Alexandra S. Latini, Nick A. Andrews, Alban Latremoliere, Michael Costigan
  • Patent number: 10350227
    Abstract: Neridronic acid, in an acid or a salt form, can be used to treat or alleviate pain or related conditions, such as complex regional pain syndrome.
    Type: Grant
    Filed: August 23, 2018
    Date of Patent: July 16, 2019
    Assignee: ANTECIP BIOVENTURES II LLC
    Inventor: Herriot Tabuteau
  • Patent number: 10342774
    Abstract: The present invention relates to a topical pharmaceutical composition comprising acitretin and a process for its preparation. It also relates to a method of treating skin disorders by administering said topical pharmaceutical composition.
    Type: Grant
    Filed: August 10, 2018
    Date of Patent: July 9, 2019
    Assignee: Sun Pharmaceutical Industries Limited
    Inventors: Rathinasabapathy Venkateshwaran, Vikas Jain, Vaibhav Dubey, Sumit Madan, Vinod Kumar Arora, Rajesh Rao